In a report released yesterday, Difei Yang from Mizuho Securities reiterated a Hold rating on Selecta Biosciences (SELB), with a price target of $2.50. The company’s shares closed last Wednesday at $3.16.
According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.5% and a 36.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
Currently, the analyst consensus on Selecta Biosciences is a Moderate Buy with an average price target of $5.40, which is an 84.3% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Selecta Biosciences’ market cap is currently $315.4M and has a P/E ratio of -3.70. The company has a Price to Book ratio of -44.34.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SELB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
